Matrix metalloproteinase in the cardiovascular remodeling of hypertension: current insights and therapeutic potential

References

• Belo VA, Parente JM, Tanus-Santos JE, Castro MM. Matrix metalloproteinase (MMP)-2 decreases calponin-1 levels and contributes to arterial remodeling in early hypertension. Biochem Pharmacol. 2016;118:50–58.
   Web of Science ®Google Scholar
• Parente JM, Pereira CA, Oliveira-Paula GH, Tanus-Santos JE, Tostes RC, Castro MM. Matrix metalloproteinase-2 activity is associated with divergent regulation of calponin-1 in conductance and resistance arteries in hypertension-induced early vascular dysfunction and remodelling. Basic Clin Pharmacol Toxicol. 2017;121:246–256.
   Web of Science ®Google Scholar
• Castro MM, Rizzi E, Figueiredo-Lopes L, et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis. 2008;198:320–331.
   PubMed Web of Science ®Google Scholar
• Castro MM, Rizzi E, Rodrigues GJ, et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med. 2009;46:1298–1307.
   PubMed Web of Science ®Google Scholar
• Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol. 2010;29:194–201.
   PubMed Web of Science ®Google Scholar
• Ceron CS, Rizzi E, Guimaraes DA, et al. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. Matrix Biol. 2012;31:261–270.
   PubMed Web of Science ®Google Scholar
• Guimaraes DA, Rizzi E, Ceron CS, et al. Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol. 2011;108:318–325.
   Web of Science ®Google Scholar
• Rizzi E, Castro MM, Prado CM, et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail. 2010;16:599–608.
   Web of Science ®Google Scholar
• Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm. 2013;2013:928315.
   PubMed Web of Science ®Google Scholar
• Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol. 2007;47:211–242.
   PubMed Web of Science ®Google Scholar
• Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation. 2010;122:2039–2047.
   PubMed Web of Science ®Google Scholar
• Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002;106:1543–1549.
   PubMed Web of Science ®Google Scholar
• Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A. 1962;48:1014–1022.
   PubMed Web of Science ®Google Scholar
• Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8:221–233.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–262.
   PubMed Web of Science ®Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–839.
   PubMed Web of Science ®Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–573.
   PubMed Web of Science ®Google Scholar
• Amin M, Pushpakumar S, Muradashvili N, Kundu S, Tyagi SC, Sen U. Regulation and involvement of matrix metalloproteinases in vascular diseases. Front Biosci (Landmark Ed). 2016;21:89–118.
   Google Scholar
• Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol. 2002;22:51–86.
   PubMed Web of Science ®Google Scholar
• Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–21494.
   PubMed Web of Science ®Google Scholar
• Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007;26:587–596.
   PubMed Web of Science ®Google Scholar
• Belo VA, Guimarães DA, Castro MM. Matrix metalloproteinase 2 as a potential mediator of vascular smooth muscle cell migration and chronic vascular remodeling in hypertension. J Vasc Res. 2015;52:221–231.
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.
   PubMed Web of Science ®Google Scholar
• Lovett DH, Mahimkar R, Raffai RL, et al. N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS One. 2013;8:e68154.
   PubMed Web of Science ®Google Scholar
• Ali MA, Chow AK, Kandasamy AD, et al. Mechanisms of cytosolic targeting of matrix metalloproteinase-2. J Cell Physiol. 2012;227:3397–3404.
   PubMed Web of Science ®Google Scholar
• Viappiani S, Nicolescu AC, Holt A, et al. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol. 2009;77:826–834.
   PubMed Web of Science ®Google Scholar
• Sariahmetoglu M, Crawford BD, Leon H, et al. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J. 2007;21:2486–2495.
   PubMed Web of Science ®Google Scholar
• Jacob-Ferreira AL, Kondo MY, Baral PK, et al. Phosphorylation status of 72 kDa MMP-2 determines its structure and activity in response to peroxynitrite. PLoS One. 2013;8:e71794.
   Web of Science ®Google Scholar
• Brew K, Dinakarpandian D, Nagase H, Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267–283.
   PubMed Web of Science ®Google Scholar
• Schulze CJ, Wang W, Suarez-Pinzon WL, Sawicka J, Sawicki G, Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial [correction of myoctardial] ischemia-reperfusion injury. Circulation. 2003;107:2487–2492.
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res. 1983;18:516–526.
   PubMed Web of Science ®Google Scholar
• Golub LM, Goodson JM, Lee HM, Vidal AM, McNamara TF, Ramamurthy NS. Tetracyclines inhibit tissue collagenases. Effects of ingested low-dose and local delivery systems. J Periodontol. 1985;56:93–97.
   Google Scholar
• Golub LM, McNamara TF, D’Angelo G, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res. 1987;66:1310–1314.
   PubMed Web of Science ®Google Scholar
• Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6:480–498.
   PubMed Web of Science ®Google Scholar
• Rossello A, Nuti E, Orlandini E, et al. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg Med Chem. 2004;12:2441–2450.
   Web of Science ®Google Scholar
• Yamada A, Uegaki A, Nakamura T, Ogawa K. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000;49:144–146.
   PubMed Web of Science ®Google Scholar
• Gatto C, Rieppi M, Borsotti P, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res. 1999;5:3603–3607.
   PubMed Web of Science ®Google Scholar
• Golub LM, Sorsa T, Lee HM, et al. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol. 1995;22:100–109.
   PubMed Web of Science ®Google Scholar
• Castro MM, Tanus-Santos JE. Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations. Curr Drug Targets. 2013;14:335–343.
   Web of Science ®Google Scholar
• Hopps E, Caimi G. Matrix metalloproteases as a pharmacological target in cardiovascular diseases. Eur Rev Med Pharmacol Sci. 2015;19:2583–2589.
   PubMed Web of Science ®Google Scholar
• Hughes BG, Schulz R. Targeting MMP-2 to treat ischemic heart injury. Basic Res Cardiol. 2014;109:424.
   Web of Science ®Google Scholar
• Martinez-Lemus LA, Hill MA, Meininger GA. The plastic nature of the vascular wall: a continuum of remodeling events contributing to control of arteriolar diameter and structure. Physiology (Bethesda). 2009;24:45–57.
   PubMed Web of Science ®Google Scholar
• Mulvany MJ. Vascular remodelling of resistance vessels: can we define this? Cardiovasc Res. 1999;41:9–13.
   PubMed Web of Science ®Google Scholar
• Briones AM, Xavier FE, Arribas SM, et al. Alterations in structure and mechanics of resistance arteries from ouabain-induced hypertensive rats. Am J Physiol Heart Circ Physiol. 2006;291:H193–H201.
   Web of Science ®Google Scholar
• Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension. 2005;45:432–437.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang J, Telljohann R, et al. Chronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressure. Hypertension. 2012;60:459–466.
   PubMed Web of Science ®Google Scholar
• Chesler NC, Ku DN, Galis ZS. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am J Physiol. 1999;277:H2002–H2009.
   Google Scholar
• Gjesdal O, Bluemke DA, Lima JA. Cardiac remodeling at the population level--risk factors, screening, and outcomes. Nat Rev Cardiol. 2011;8:673–685.
   PubMed Web of Science ®Google Scholar
• Liu P, Sun M, Sader S. Matrix metalloproteinases in cardiovascular disease. Can J Cardiol. 2006;22(Suppl B):25B–30B.
   PubMed Web of Science ®Google Scholar
• Wang M, Kim SH, Monticone RE, Lakatta EG. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension. 2015;65:698–703.
   PubMed Web of Science ®Google Scholar
• Bergman MR, Teerlink JR, Mahimkar R, et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H1847–H1860.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res. 2007;74:196–206.
   PubMed Web of Science ®Google Scholar
• Rizzi E, Castro MM, Ceron CS, et al. Tempol inhibits TGF-β and MMPs upregulation and prevents cardiac hypertensive changes. Int J Cardiol. 2013;165:165–173.
   Web of Science ®Google Scholar
• Wang M, Zhao D, Spinetti G, et al. Matrix metalloproteinase 2 activation of transforming growth factor-beta1 (TGF-beta1) and TGF-beta1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol. 2006;26:1503–1509.
   PubMed Web of Science ®Google Scholar
• Ceron CS, Rizzi E, Guimarães DA, Martins-Oliveira A, Gerlach RF, Tanus-Santos JE. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension. Free Radic Biol Med. 2013;65:47–56.
   PubMed Web of Science ®Google Scholar
• Iwazu Y, Muto S, Hirahara I, Fujisawa G, Takeda S, Kusano E. Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive rats. J Hypertens. 2011;29:2440–2453.
   Web of Science ®Google Scholar
• Dwivedi A, Slater SC, George SJ. MMP-9 and -12 cause N-cadherin shedding and thereby β-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res. 2009;81:178–186.
   Web of Science ®Google Scholar
• Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85:906–911.
   PubMed Web of Science ®Google Scholar
• Abdalvand A, Morton JS, Bourque SL, Quon AL, Davidge ST. Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow. Hypertension. 2013;61:488–493.
   PubMed Web of Science ®Google Scholar
• Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res. 2000;87:670–676.
   PubMed Web of Science ®Google Scholar
• Martínez A, Oh HR, Unsworth EJ, et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J. 2004;383:413–418.
   PubMed Web of Science ®Google Scholar
• Nascimento RA, Mendes G, Possomato-Vieira JS, et al. Metalloproteinase inhibition protects against reductions in circulating adrenomedullin during lead-induced acute hypertension. Basic Clin Pharmacol Toxicol. 2015;116:508–515.
   Web of Science ®Google Scholar
• Nagareddy PR, Rajput PS, Vasudevan H, et al. Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats. Br J Pharmacol. 2012;165:705–715.
   Web of Science ®Google Scholar
• Rodrigues SF, Tran ED, Fortes ZB, Schmid-Schönbein GW. Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2010;299:H25–H35.
   Web of Science ®Google Scholar
• DeLano FA, Schmid-Schönbein GW. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension. 2008;52:415–423.
   PubMed Web of Science ®Google Scholar
• Tran ED, DeLano FA, Schmid-Schönbein GW. Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction. J Vasc Res. 2010;47:423–431.
   PubMed Web of Science ®Google Scholar
• Barhoumi T, Fraulob-Aquino J, Mian MOR, et al. Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury. Cardiovasc Res. 2017;113:1753–1762.
   PubMed Web of Science ®Google Scholar
• Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol. 1998;161:3340–3346.
   PubMed Web of Science ®Google Scholar
• Krishnan SM, Sobey CG, Latz E, Mansell A, Drummond GR. IL-1β and IL-18: inflammatory markers or mediators of hypertension? Br J Pharmacol. 2014;171:5589–5602.
   PubMed Web of Science ®Google Scholar
• Chen AY, Ha JN, Delano FA, Schmid-Schönbein GW. Receptor cleavage and P-selectin-dependent reduction of leukocyte adhesion in the spontaneously hypertensive rat. J Leukoc Biol. 2012;92:183–194.
   Web of Science ®Google Scholar
• McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 2000;289:1202–1206.
   PubMed Web of Science ®Google Scholar
• Tong S, Neboori HJ, Tran ED, Schmid-Schönbein GW. Constitutive expression and enzymatic cleavage of ICAM-1 in the spontaneously hypertensive rat. J Vasc Res. 2011;48:386–396.
   PubMed Web of Science ®Google Scholar
• Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-López NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol. 2007;43:429–436.
   PubMed Web of Science ®Google Scholar
• Sawicki G, Leon H, Sawicka J, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation. 2005;112:544–552.
   PubMed Web of Science ®Google Scholar
• Ali MA, Fan X, Schulz R. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc Med. 2011;21:112–118.
   PubMed Web of Science ®Google Scholar
• Buchholz B, Perez V, Siachoque N, et al. Dystrophin proteolysis: a potential target for MMP-2 and its prevention by ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2014;307:H88–H96.
   Web of Science ®Google Scholar
• Schulze CJ, Castro MM, Kandasamy AD, et al. Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass. Crit Care Med. 2013;41:2512–2520.
   Web of Science ®Google Scholar
• Takahashi K, Hiwada K, Kokubu T. Vascular smooth muscle calponin. A novel troponin T-like protein. Hypertension. 1988;11:620–626.
   PubMed Web of Science ®Google Scholar
• Winder SJ, Walsh MP. Smooth muscle calponin. Inhibition of actomyosin MgATPase and regulation by phosphorylation. J Biol Chem. 1990;265:10148–10155.
   PubMed Web of Science ®Google Scholar
• North AJ, Gimona M, Cross RA, Small JV. Calponin is localised in both the contractile apparatus and the cytoskeleton of smooth muscle cells. J Cell Sci. 1994;107(Pt 3):437–444.
   Google Scholar
• Gimona M, Herzog M, Vandekerckhove J, Small JV. Smooth muscle specific expression of calponin. FEBS Lett. 1990;274:159–162.
   PubMed Web of Science ®Google Scholar
• Hu JJ, Ambrus A, Fossum TW, Miller MW, Humphrey JD, Wilson E. Time courses of growth and remodeling of porcine aortic media during hypertension: a quantitative immunohistochemical examination. J Histochem Cytochem. 2008;56:359–370.
   Web of Science ®Google Scholar
• Pfisterer L, Feldner A, Hecker M, Korff T. Hypertension impairs myocardin function: a novel mechanism facilitating arterial remodelling. Cardiovasc Res. 2012;96:120–129.
   PubMed Web of Science ®Google Scholar
• Walter A, Etienne-Selloum N, Sarr M, Kane MO, Beretz A, Schini-Kerth VB. Angiotensin II induces the vascular expression of VEGF and MMP-2 in vivo: preventive effect of red wine polyphenols. J Vasc Res. 2008;45:386–394.
   PubMed Web of Science ®Google Scholar
• Care AS, Sung MM, Panahi S, et al. Perinatal resveratrol supplementation to spontaneously hypertensive rat dams mitigates the development of hypertension in adult offspring. Hypertension. 2016;67:1038–1044.
   Web of Science ®Google Scholar
• Wang L, Cheng X, Li H, et al. Quercetin reduces oxidative stress and inhibits activation of cJun N-terminal kinase/activator protein-1 signaling in an experimental mouse model of abdominal aortic aneurysm. Mol Med Rep. 2014;9:435–442.
   Web of Science ®Google Scholar
• Barteková M, Šimončíková P, Fogarassyová M, et al. Quercetin improves postischemic recovery of heart function in doxorubicin-treated rats and prevents doxorubicin-induced matrix metalloproteinase-2 activation and apoptosis induction. Int J Mol Sci. 2015;16:8168–8185.
   PubMed Web of Science ®Google Scholar
• Pereira, SC, Parente, JM, Belo, VA, et al., Quercetin decreases the activity of matrix metalloproteinase-2 and ameliorates vascular remodeling in renovascular hypertension. Atherosclerosis. 2018;270:146–153.
   Web of Science ®Google Scholar
• Navarro JA, de Gouveia LA, Rocha-Penha L, et al. Reduced levels of potential circulating biomarkers of cardiovascular diseases in apparently healthy vegetarian men. Clin Chim Acta. 2016;461:110–113.
   PubMed Web of Science ®Google Scholar
• Castro MM, Rizzi E, Ceron CS, et al. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. Nitric Oxide. 2012;26:162–168.
   PubMed Web of Science ®Google Scholar
• Fortuño A, Bidegain J, Robador PA, et al. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. Hypertension. 2009;54:744–750.
   PubMed Web of Science ®Google Scholar
• Brassard P, Amiri F, Schiffrin EL. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension. 2005;46:598–606.
   PubMed Web of Science ®Google Scholar
• Martins-Oliveira A, Castro MM, Oliveira DM, et al. Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling. Int J Cardiol. 2013;167:1199–1205.
   PubMed Web of Science ®Google Scholar
• Fontana V, Silva PS, Izidoro-Toledo TC, et al. Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension. Cardiovasc Drugs Ther. 2012;26:511–519.
   Web of Science ®Google Scholar
• Derosa G, Maffioli P, Ferrari I, et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res. 2011;34:145–151.
   PubMed Web of Science ®Google Scholar
• Yamada T, Nagata K, Cheng XW, et al. Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol. 2009;615:163–170.
   PubMed Web of Science ®Google Scholar
• Martinez ML, Castro MM, Rizzi E, et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol. 2008;591:224–230.
   PubMed Web of Science ®Google Scholar
• Marçal DM, Rizzi E, Martins-Oliveira A, et al. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:35–44.
   PubMed Web of Science ®Google Scholar
• Rizzi E, Guimaraes DA, Ceron CS, et al. β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy. Free Radic Biol Med. 2014;73:308–317.
   Web of Science ®Google Scholar
• Ceron CS, Castro MM, Rizzi E, et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol. 2010;160:77–87.
   Web of Science ®Google Scholar
• Veliotes DG, Norton GR, Correia RJ, et al. Impact of aldosterone receptor blockade on the deleterious cardiac effects of adrenergic activation in hypertensive rats. J Cardiovasc Pharmacol. 2010;56:203–211.
   Web of Science ®Google Scholar